
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2918030/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Balloon pulmonary angioplasty in chronic thromboembolic pulmonary hypertension: a multicentre registry. EuroIntervention, 2022, 17, 1104-1111.	3.2	23
2	The impact of complications related to transvenous lead extraction on the 12-month prognosis: Insights from the SILCARD registry. Kardiologia Polska, 2022, 80, 64-71.	0.6	1
3	Lead Dependent Tricuspid Valve Dysfunction-Risk Factors, Improvement after Transvenous Lead Extraction and Long-Term Prognosis. Journal of Clinical Medicine, 2022, 11, 89.	2.4	5
4	The role of cardiac surgeon in transvenous lead extraction: Experience from 3462 procedures. Journal of Cardiovascular Electrophysiology, 2022, , .	1.7	4
5	Safety and Effectiveness of Transvenous Lead Extraction in Patients with Infected Cardiac Resynchronization Therapy Devices; Is It More Risky than Extraction of Other Systems?. International Journal of Environmental Research and Public Health, 2022, 19, 5803.	2.6	2
6	Lead Extraction and Re-Extractions - Inherent Parts of Permanent Pacing in Children and Young Adults. Journal of Biomedical Research & Environmental Sciences, 2022, 3, 221-226.	0.2	2
7	Impact of the COVID-19 Pandemic on Pulmonary Hypertension Patients: Insights from the BNP-PL National Database. International Journal of Environmental Research and Public Health, 2022, 19, 8423.	2.6	5
8	Risk Factors and Long-Term Survival of Octogenarians and Nonagenarians Undergoing Transvenous Lead Extraction Procedures. Gerontology, 2021, 67, 36-48.	2.8	9
9	Echocardiographic findings in patients with cardiac implantable electronic devices—analysis of factors predisposing to leadâ€associated changes. Clinical Physiology and Functional Imaging, 2021, 41, 25-41.	1.2	14
10	DIAGNOSTIC AND PREDICTIVE VALUE OF RIGHT HEART CATHETERIZATION-DERIVED MEASUREMENTS IN PULMONARY HYPERTENSION. Wiadomości Lekarskie, 2021, 74, 546-553.	0.3	4
11	Characteristics and outcomes of patients with chronic thromboembolic pulmonary hypertension in the era of modern therapeutic approaches: data from the Polish multicenter registry (BNP-PL). Therapeutic Advances in Chronic Disease, 2021, 12, 204062232110029.	2.5	21
12	Prognostic Value of Preoperative Echocardiographic Findings in Patients Undergoing Transvenous Lead Extraction. International Journal of Environmental Research and Public Health, 2021, 18, 1862.	2.6	7
13	Serum Sulfhydryl Groups, Malondialdehyde, Uric Acid, and Bilirubin as Predictors of Adverse Outcome in Heart Failure Patients due to Ischemic or Nonischemic Cardiomyopathy. Oxidative Medicine and Cellular Longevity, 2021, 2021, 1-14.	4.0	9
14	The prognostic value of transesophageal echocardiography after transvenous lead extraction: landscape after battle. Cardiovascular Diagnosis and Therapy, 2021, 11, 394-410.	1.7	10
15	The role of transesophageal echocardiography in predicting technical problems and complications of transvenous lead extractions procedures. Clinical Cardiology, 2021, 44, 1233-1242.	1.8	9
16	Influence of the type of pathogen on the clinical course of infectious complications related to cardiac implantable electronic devices. Scientific Reports, 2021, 11, 14864.	3.3	5
17	Transvenous Lead Extraction without Procedure-Related Deaths in 1000 Consecutive Patients: A Single-Center Experience. Vascular Health and Risk Management, 2021, Volume 17, 445-459.	2.3	11
18	Analysis of Risk Factors for Major Complications of 1500 Transvenous Lead Extraction Procedures with Especial Attention to Tricuspid Valve Damage. International Journal of Environmental Research and Public Health, 2021, 18, 9100.	2.6	13

#	Article	IF	CITATIONS
19	The Influence of Lead-Related Venous Obstruction on the Complexity and Outcomes of Transvenous Lead Extraction. International Journal of Environmental Research and Public Health, 2021, 18, 9634.	2.6	13
20	A Study of Major and Minor Complications of 1500 Transvenous Lead Extraction Procedures Performed with Optimal Safety at Two High-Volume Referral Centers. International Journal of Environmental Research and Public Health, 2021, 18, 10416.	2.6	13
21	Risk Factors for Lead-Related Venous Obstruction: A Study of 2909 Candidates for Lead Extraction. Journal of Clinical Medicine, 2021, 10, 5158.	2.4	5
22	DIAGNOSTIC AND PREDICTIVE VALUE OF RIGHT HEART CATHETERIZATION-DERIVED MEASUREMENTS IN PULMONARY HYPERTENSION. Wiadomości Lekarskie, 2021, 74, 546-553.	0.3	0
23	Risk of Complications and Survival of Patients Dialyzed with Permanent Catheters. Medicina (Lithuania), 2020, 56, 2.	2.0	4
24	Nitric Oxide Stroke Volume Index as a New Hemodynamic Prognostic Parameter for Patients with Pulmonary Arterial Hypertension. Journal of Clinical Medicine, 2020, 9, 2939.	2.4	2
25	Transesophageal Echocardiography as a Monitoring Tool during Transvenous Lead Extraction—Does It Improve Procedure Effectiveness?. Journal of Clinical Medicine, 2020, 9, 1382.	2.4	18
26	A new approach to the continuous monitoring of transvenous lead extraction using transesophageal echocardiography—Analysis of 936 procedures. Echocardiography, 2020, 37, 601-611.	0.9	16
27	Transvenous Lead Extraction SAFeTY Score for Risk Stratification and Proper Patient Selection for Removal Procedures Using Mechanical Tools. Journal of Clinical Medicine, 2020, 9, 361.	2.4	46
28	Ceruloplasmin, NT-proBNP, and Clinical Data as Risk Factors of Death or Heart Transplantation in a 1-Year Follow-Up of Heart Failure Patients. Journal of Clinical Medicine, 2020, 9, 137.	2.4	1
29	Characterization of Patients with Pulmonary Arterial Hypertension: Data from the Polish Registry of Pulmonary Hypertension (BNP-PL). Journal of Clinical Medicine, 2020, 9, 173.	2.4	38
30	Remote Supervision to Decrease Hospitalization Rate (RESULT) study in patients with implanted cardioverter-defibrillator. Europace, 2020, 22, 769-776.	1.7	26
31	Transesophageal echocardiography for the monitoring of transvenous lead extraction. Kardiologia Polska, 2020, 78, 1206-1214.	0.6	11
32	Infection-related complications in patients with end stage renal failure dialyzed through a permanent catheter. Acta Angiologica, 2020, 26, 9-18.	0.1	0
33	Malondialdehyde and Uric Acid as Predictors of Adverse Outcome in Patients with Chronic Heart Failure. Oxidative Medicine and Cellular Longevity, 2019, 2019, 1-15.	4.0	20
34	Comparison of Oxidative Stress Parameters in Heart Failure Patients Depending on Ischaemic or Nonischaemic Aetiology. Oxidative Medicine and Cellular Longevity, 2019, 2019, 1-13.	4.0	28
35	To abandon or not to abandon: Late consequences of pacing and ICD lead abandonment. PACE - Pacing and Clinical Electrophysiology, 2019, 42, 1006-1017.	1.2	26
36	Superoxide dismutase activity as a predictor of adverse outcomes in patients with nonischemic dilated cardiomyopathy. Cell Stress and Chaperones, 2019, 24, 661-673.	2.9	21

#	Article	IF	CITATIONS
37	The multiple systemic artery to pulmonary artery fistulas resulting in severe irreversible pulmonary arterial hypertension in patient with previous history of pneumothorax. BMC Pulmonary Medicine, 2019, 19, 80.	2.0	4
38	Safety and effectiveness of coronary sinus leads extraction – single high-volume centre experience. Postepy W Kardiologii Interwencyjnej, 2019, 15, 345-356.	0.2	2
39	Database of Pulmonary Hypertension in the Polish Population (BNP‑PL): design of the registry. Kardiologia Polska, 2019, 77, 972-974.	0.6	18
40	Prognosis of patients with implanted pacemakers in 4â€'year follow-up. Herz, 2018, 43, 315-324.	1.1	2
41	Effectiveness, safety, and long-term outcomes of non-powered mechanical sheaths for transvenous lead extraction. Europace, 2018, 20, 1324-1333.	1.7	31
42	Prognostic Factors in Patients with an Implanted Pacemaker after 80 Years of Age in a 4-Year Follow-Up. Gerontology, 2018, 64, 107-117.	2.8	10
43	Risk Factors Predicting Complications of Transvenous Lead Extraction. BioMed Research International, 2018, 2018, 1-14.	1.9	26
44	Lead-related infective endocarditis: factors influencing the formation of large vegetations. Europace, 2017, 19, euw121.	1.7	13
45	Serum Galectin-3 and ST2 as predictors of unfavorable outcome in stable dilated cardiomyopathy patients. Hellenic Journal of Cardiology, 2017, 58, 350-359.	1.0	21
46	Impact of ICD lead on the system durability, predictors of longâ€ŧerm survival following ICD system extraction. PACE - Pacing and Clinical Electrophysiology, 2017, 40, 1139-1146.	1.2	6
47	Lead-related infective endocarditis: Factors influencing early and long-term survival in patients undergoing transvenous lead extraction. Heart Rhythm, 2017, 14, 43-49.	0.7	30
48	An implantable pump Lenus pro \hat{A}^{\otimes} in the treatment of pulmonary arterial hypertension with intravenous treprostinil. BMC Pulmonary Medicine, 2017, 17, 162.	2.0	16
49	Infectious complications in patients with cardiac implantable electronic devices – risk factors, prevention and prognosis. Polish Archives of Internal Medicine, 2017, 127, 597-607.	0.4	11
50	WpÅ,yw BMI, stęŹ⁄4enia leptyny i adiponektyny na rokowanie u pacjentów z niedokrwiennÄ kardiomiopatiÄ rozstrzeniowÄ Endokrynologia Polska, 2017, 68, 26-34.	``1. 0	13
51	Leads dislodged into the pulmonary vascular bed in patients with cardiac implantable electronic devices. Postepy W Kardiologii Interwencyjnej, 2016, 4, 348-354.	0.2	5
52	Handheld Capillary Blood Lactate Analyzer as an Accessible and Cost-Effective Prognostic Tool for the Assessment of Death and Heart Failure Occurrence during Long-Term Follow-Up. Disease Markers, 2016, 2016, 1-7.	1.3	2
53	The influence of obstructive sleep breathing disturbances on echocardiographic and pulmonary haemodynamic parameters in patients with dilated cardiomyopathy. Kardiologia Polska, 2016, 74, 135-141.	0.6	3
54	Leadâ€Dependent Infective Endocarditis: The Role of Factors Predisposing to Its Development in an Analysis of 414 Clinical Cases. PACE - Pacing and Clinical Electrophysiology, 2015, 38, 846-856.	1.2	17

#	Article	IF	CITATIONS
55	Upgrade from ICD to CRT-D: clinical and haemodynamic impact of biventricular pacing in a patient with acquired long QT syndrome. Open Medicine (Poland), 2015, 10, 113-118.	1.3	0
56	Randomized placebo controlled blinded study to assess valsartan efficacy in preventing left ventricle remodeling in patients with dual chamber pacemaker — Rationale and design of the trial. Contemporary Clinical Trials, 2015, 42, 239-243.	1.8	2
57	Clinical Significance of Viral Genome Persistence in the Myocardium of Patients with Dilated Cardiomyopathy. Intervirology, 2015, 58, 350-356.	2.8	12
58	Transcutaneous intravascular transposition of aÂpermanent dialysis catheter. Wideochirurgia I Inne Techniki Maloinwazyjne, 2014, 3, 486-488.	0.7	0
59	Evaluation of CD25+CD4+ Regulatory T-Lymphocyte Subpopulations in Coronary Artery Diseases Patients. ISRN Biomarkers, 2014, 2014, 1-5.	0.5	0
60	Oxidative Stress Markers and C-Reactive Protein Are Related to Severity of Heart Failure in Patients with Dilated Cardiomyopathy. Mediators of Inflammation, 2014, 2014, 1-10.	3.0	38
61	Neopterin and Beta-2 Microglobulin Relations to Immunity and Inflammatory Status in Nonischemic Dilated Cardiomyopathy Patients. Mediators of Inflammation, 2014, 2014, 1-8.	3.0	7
62	PM001 Randomized Placebo Controlled Study To Assess Valsartan Efficacy In Preventing Left Ventricle Remodeling In Patients With Dual Chamber Pacemaker - Rationale ofÂThe Trial. , 2014, 9, e62.		0
63	Therapeutic percutaneous transluminal angioplasty with a stenting procedure of a stenosed great cardiac vein in a patient with dilated cardiomyopathy submitted to biventricular pacemaker implantation. Cor Et Vasa, 2013, 55, e541-e544.	0.1	0
64	Comparison of Coronary Artery Bypass Grafting with Percutaneous Coronary Intervention for Unprotected Left Main Coronary Artery Disease. Yonsei Medical Journal, 2012, 53, 58.	2.2	10
65	Tako-tsubo cardiomyopathy as a recurrent disease with doubtful prognosis of recovery and heterogenic symptoms. Cardiology Journal, 2012, 19, 521-523.	1.2	4
66	Cardiogenic shock in myocardial infarction-results of in-hospital follow-up. Open Medicine (Poland), 2011, 6, 213-219.	1.3	0
67	Heart Failure Mimicking Prior Myocardial Infarction in a Patient With Idiopathic Hypereosinophilic Syndrome. International Heart Journal, 2011, 52, 194-196.	1.0	3
68	Long-term Exposure to Acetaminophen is a Crucial for Activity of Selected Antioxidative Enzymes and Level of Lipid Peroxidation Process in Rat Liver. Journal of Bioequivalence & Bioavailability, 2011, 03, .	0.1	5
69	Analysis of Myocardial Infarction Time Course in Women Compared With Men in Upper Silesia Population in 30 Day Follow-Up. International Heart Journal, 2009, 50, 711-721.	1.0	2
70	Expression of TGF-β1 and its receptor genes (TβR I, TβR II, and TβR III-betaglycan) in peripheral blood leucocytes in patients with idiopathic pulmonary arterial hypertension and Eisenmenger's syndrome. International Journal of Molecular Medicine, 2008, , .	4.0	4
71	Post-Dilatation Intravascular Brachytherapy Trials on Hypercholesterolemic Rabbits Using 32P-Phosphate Solutions in Angioplasty Balloons. CardioVascular and Interventional Radiology, 2004, 27, 42-50.	2.0	4
72	32P liquid sources—comparison of the effectiveness of postangioplasty versus poststenting intravascular brachytherapy in hypercholesterolemic rabbits. Cardiovascular Radiation Medicine, 2003, 4, 64-68.	0.6	4

#	Article	IF	CITATIONS
73	Lipid peroxidation and vitamin E in human coronary atherosclerotic lesions. Clinica Chimica Acta, 2003, 330, 121-129.	1.1	6
74	Evidence of oxidative stress in the renal cortex of diabetic rats: favourable effect of vitamin E. Scandinavian Journal of Clinical and Laboratory Investigation, 2002, 62, 81-88.	1.2	18
75	Post-stenting Intravascular Brachytherapy Trials on Hypercholesterolemic Rabbits Using 32P Liquid Sources: Implications for Prevention of In-Stent Restenosis. CardioVascular and Interventional Radiology, 2002, 25, 307-313.	2.0	4
76	Total Antioxidant Capacity, Uric Acid, and Bilirubin in Patients with Heart Failure due to Non-Ischemic Cardiomyopathy. , 0, , .		1